{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"20.4","value":"11.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Estimated using the product-limit method of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 1000mg/m\\^2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 1.4mg/m\\^2 eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nEribulin Mesylate: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Eribulin Mesylate and Gemcitabine Hydrochloride)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From start of treatment until death from any cause ,up to 36 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}